bacitracin injection, powder, for solution
xellia pharmaceuticals usa llc - bacitracin (unii: 58h6rwo52i) (bacitracin - unii:58h6rwo52i) - in accordance with the statements in the "warning box" the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs, bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in those individuals with a history of previous hypersensitivity or toxic reaction to it.
bacitracin zinc and polymyxin b sulfate ointment
direct_rx - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin b sulfate. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components.
bacitracin injection, powder, for solution
civica, inc. - bacitracin (unii: 58h6rwo52i) (bacitracin - unii:58h6rwo52i) - in accordance with the statements in the "warning box" the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs, bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in those individuals with a history of previous hypersensitivity or toxic reaction to it.
jamp-bacitracine ointment
jamp pharma corporation - bacitracin - ointment - 500unit - bacitracin 500unit - antibiotics
bacitracin zinc 15% granule
panfast marketing (m) sdn bhd - bacitracin zinc -
bacitracin zinc 15% powder
panfast marketing (m) sdn bhd - bacitracin zinc -
bacitracin methylene disalicylate 15% granule
panfast marketing (m) sdn bhd - bacitracin methylene disalicylate -
bacitracin zinc
dechra veterinary products (australia) pty. ltd. - bacitracin zinc - unknown - bacitracin zinc antibiotic active 0.0 - active constituent
bacitracin zinc
nutriment health pty ltd - bacitracin zinc - unknown - bacitracin zinc antibiotic active 0.0 - active constituent
bacitracin zinc
huvepharma eood - bacitracin zinc - unknown - bacitracin zinc antibiotic active 0.0 - active constituent